Clinical Characteristics and Survival of Patients with Idiopathic Pulmonary Fibrosis: Analysis of the Serbian Cohort from the EMPIRE Registry
Authors:
- Sanja Dimic-JanjicSDSanja Dimic-Janjic
- Mihailo StjepanovicMSMihailo Stjepanovic
- Slobodan BelicSBSlobodan Belic
- Dragan VukosavljevicDVDragan Vukosavljevic
- Ivan MilivojevicIMIvan Milivojevic
- Nikola TrboljevacNTNikola Trboljevac
- Nikola NikolicNNNikola Nikolic
- Slavko StamenicSSSlavko Stamenic
- Maja StojanovicMaja Stojanovic
- Kristina StosicKSKristina Stosic
- Martina Koziar VasakovaMVMartina Koziar Vasakova
- Ruza StevicRSRuza Stevic
Open Access
- 22 August 2025
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2121
Abstract
Background/Objectives: Idiopathic pulmonary fibrosis (IPF) registries are established to enhance understanding of its natural history. Methods: Serbia (RS) participated in the EMPIRE (European Multi-Partner IPF Registry) from June 2015 to October 2022, involving four centers. The registry included patients over 18 diagnosed with IPF based on the 2011 international criteria. We aimed to gather key clinical, functional, and survival data, along with treatment information for IPF patients in RS, using a centralized electronic case report for consistency. Results: 188 RS patients participated (median age at diagnosis 65, 63.8% male, 51% smoking history, 56% radiological usual interstitial pneumonia (UIP) pattern). At the diagnosis, median forced vital capacity (FVC) was 73.7% and diffusion capacity for carbon monoxide (DLCO) was 38%. At initiation of antifibrotic therapy, median FVC was 73.2% (71.5% for deceased, 75.8% for survivors (p = 0.455), and DLCO was 33.8% (19.9% for deceased, and 35.6% for survivors (p = 0.046)). The median long-term survival from diagnosis was 29.4 months (95% CI: 22.6–36.2 months), and 9.4 months (95% CI: 5.9–12.9 months) from the initiation of therapy, with no difference in the duration of antifibrotic treatment between survivors and deceased (p = 0.598). Conclusions: The RS EMPIRE cohort represents a younger, less comorbid population with fewer smokers and more probable UIP, factors linked to a favorable prognosis. Nevertheless, survival was poorer than expected, mainly due to advanced disease severity at the time of antifibrotic initiation, as indicated by lower DLCO. These findings highlight the importance of earlier diagnosis and treatment before significant physiological decline to improve outcomes.Keywords
This publication has 32 references indexed in Scilit:
- Single-cell RNA sequencing reveals special basal cells and fibroblasts in idiopathic pulmonary fibrosisScientific Reports, 2024
- Idiopathic pulmonary fibrosis: Pathophysiology, cellular signaling, diagnostic and therapeutic approachesMedicine in Drug Discovery, 2023
- Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventionsMolecular and Cellular Biochemistry, 2023
- Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosisJournal of Medical Economics, 2022
- Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the HydraBritish Journal of Pharmacology, 2020
- CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) IN THE US: DATA FROM THE IPF-PRO REGISTRYChest, 2018
- Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future PerspectivesCanadian Respiratory Journal, 2017
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Prognostic Factors in Idiopathic Pulmonary FibrosisThe American Journal of the Medical Sciences, 2009